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Abstract
Background: The proportion of pregnant women who have a caesarean section shows a wide variation across
Europe, and concern exists that these proportions are increasing. Much of the increase in caesarean sections in
recent years is due to a cascade effect in which a woman who has had one caesarean section is much more likely
to have one again if she has another baby. In some places, it has become common practice for a woman who has
had a caesarean section to have this procedure again as a matter of routine. The alternative, vaginal birth after
caesarean (VBAC), which has been widely recommended, results in fewer undesired results or complications and is
the preferred option for most women. However, VBAC rates in some countries are much lower than in other
countries.
Methods/Design: The OptiBIRTH trial uses a cluster randomised design to test a specially developed approach
to try to improve the VBAC rate. It will attempt to increase VBAC rates from 25 % to 40 % through increased
women-centred care and women’s involvement in their care. Sixteen hospitals in Germany, Ireland and Italy
agreed to join the study, and each hospital was randomly allocated to be either an intervention or a control
site.
Discussion: If the OptiBIRTH intervention succeeds in increasing VBAC rates, its application across Europe
might avoid the 160,000 unnecessary caesarean sections that occur every year at an extra direct annual cost
of more than €150 million.
Trial registration: Current Controlled Trials ISRCTN10612254, registered 3 April 2013.
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Background
Concern has been expressed globally at the rising
caesarean section rate. For example, the World Health
Organization (WHO) recently noted that ‘caesarean
section rates higher than 10 % are not associated with
reductions in maternal and new-born mortality rates’
[38]. In the United States in 2012, the caesarean section
rate rose for the twelfth consecutive year to 32.8 %, a
proportional increase of 56 % since 1996 [24]. In Europe,
the caesarean section rate increased between 1999 and
2005 in all European Union member countries for which
data were available [5]. In 2010, Italy had a caesarean
section rate of 38 %, whereas the rate was 17 % in the
Netherlands, indicating wide variations in maternity care
practices within Europe [12, 23]. Some of the reasons
that have been offered for the continuing increase in
caesarean sections include medico-legal issues, the in-
creasing use of electronic foetal heart rate monitoring,
and reduced training in operative vaginal and vaginal
breech births [1, 2, 19]. Maternal request for caesarean
section, that is, a caesarean section in the absence of
medically indicated reasons, is a further frequently cited
reason for increasing caesarean section rates, ranging
from 2.6 % to 26.8 % of all caesarean sections [20, 32].
The most common reason, however, is repeat caesarean
section following previous caesarean section [27], and
this is a significant factor contributing to the overall in-
creased caesarean section rates. Repeat caesarean section
accounts for more than one-third of all caesarean sec-
tions in the United States [7].
Vaginal birth after caesarean (VBAC) is a safe alterna-
tive to repeat caesarean section, is preferred by most
women and is deemed to be a key way of reducing
overall caesarean section rates (Cunningham 2010).
However, VBAC rates, which rose steadily across the
world in the early 1990s, have declined dramatically
again. In 2006, for example, approximately 8 % of
women in the US who had a previous caesarean section
had a VBAC in their next pregnancy (Cunningham
2010). Other reports indicate VBAC rates of between
30 % and 56 % [4, 37]. In Europe, wide variations in
VBAC rates exist between and within countries, reflect-
ing variations in maternity care practices and maternity
care provision. For example, VBAC rates in Germany,
Ireland and Italy have been found to be significantly
lower (29 to 36 %) than those in the Netherlands,
Sweden and Finland (45 to 55 %) [11]. Combined
with the high caesarean section rates in some coun-
tries, such as Italy, this means that many women in
Europe are unlikely to have a vaginal birth unless
they indicate that they would prefer that over a cae-
sarean section [10].
A number of reasons are offered for the variations in
VBAC rates. These include medico-legal factors and the
inaccessibility of tertiary care centres, but variations in
caesarean section rates are more likely to reflect national
and individual clinician’s approaches to clinical decision-
making [18]. Of the women who do choose and are
supported to have a planned VBAC, VBAC success is
considerably higher (70 % to 87 %) than the average
rates (Cunningham 2010, [13]). This indicates that
VBAC is a real and viable option for most women with
previous caesarean section.
Increasing the caesarean section rates in conjunc-
tion with declining VBAC rates is a maternity care
issue of particular concern. If caesarean section rates
continue to rise at the rate of recent years, the pro-
jected overall caesarean section rate by 2020 will be
56 % [36]. Considering the increased adverse maternal
and neonatal outcomes associated with caesarean sec-
tion [9, 15–17, 21, 25, 28, 37], this trend and its po-
tential effects on the health of women and babies
into the future requires more attention. A dedicated
and concerted effort by women and clinicians has the
potential to halt increasing caesarean section rates
[3], increase VBAC rates [33] and improve the overall
maternal and neonatal health and wellbeing of women
and their babies.
The OptiBIRTH trial, conducted across different
European health settings, involves unique collaborative
efforts of women and clinicians. It seeks to enhance
women-centred maternity care and, through the devel-
opment and testing of an innovative complex interven-
tion aimed at increasing VBAC rates in high caesarean
section and low VBAC countries, reduce the fragmenta-
tion and lack of coherence in health service delivery.
The OptiBIRTH trial will provide evidence to inform the
organisation and provision of maternity care for many
hundreds of thousands of women with previous caesarean
section in Europe. Two systematic reviews of existing
evidence have been published as part of the wider
OptiBIRTH project: one on women-centred interven-
tions and one on clinician-centred interventions for
increasing VABC rates [22, 30]. These provide justifi-
cation for this trial and assisted in the design of the
OptiBIRTH intervention.
This protocol sets out the design of the OptiBIRTH
trial and has been prepared in accordance with the
SPIRIT guidelines for the protocol for a randomised trial
[6]. Findings of the trial will be reported in accordance
with the CONSORT recommendations [26].
Aim
The aim of the OptiBIRTH project, of which this trial is
one component, is to improve maternal health service
delivery, and optimise childbirth by increasing vaginal
birth after caesarean section through enhanced women-
centred maternity care across Europe.
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Objectives
The objective of this trial is to compare the effects of an
intervention that has been developed with the intention
of maximising VBAC versus usual care. This will be
done through a cluster randomised trial in maternity
units in three European countries with relatively low
VBAC rates. The intervention was developed within
the OptiBIRTH project and includes an effort to de-
velop communities of practice in the intervention
sites through face-to-face and online activities.
Registration
The OptiBIRTH trial was prospectively registered in
the ISRCTN Registry before randomisation was done
(ISRCTN applied for: 17 March 2013; ISRCTN assigned:
3 April 2013; and randomisation conducted: 7 April
2013). The trial was assigned the following number:
ISRCTN10612254.
Study setting
A total of 16 sites (maternity units) agreed to take part
in the OptiBIRTH trial initially: five from Ireland, five
from Italy and six from Germany. In order to be eligible
for participation, each site had to have a VBAC rate of
less than 35 % and to provide a letter from the lead ob-
stetrician (and, when available, the lead midwife) stating
that they were willing for their institution to join the
study. However, one of the German sites was withdrawn
from the trial because of failure to recruit any partici-
pants in the first 6 months.
Methods/Design
Design
This is a cluster randomised trial of maternity units
in three countries with relatively low VBAC rates
(Germany, Ireland and Italy). The units represent a
variety of healthcare settings (small, medium and
large units, with annual births of 2,000 to 8,500) in
both urban and rural locations [14]. For the purposes
of the randomisation, two maternity units in the same
city in Germany were considered as a single cluster
for the purposes of the trial.
Pilot study
A pilot study was conducted from January 2014 in
Germany and February 2014 in Ireland and Italy, with
sites having been pre-randomised to the intervention or
control (see below). This pilot was used to identify
problems with the research design and trial processes, to
refine data collection and to examine selection and en-
rolment processes. The pilot concluded in March 2014
in Ireland and in April 2014 in Germany and Italy. The
main analysis for OptiBIRTH will exclude women re-
cruited during the pilot trial. It will include data on
women who gave their consent on or after 1 April 2014
in Ireland and 1 May 2015 in Germany and Italy.
Randomisation
The unit of randomisation in the trial is the maternity
unit (the ‘site’). Randomisation had to be done in ad-
vance of recruiting women to participate in the trial to
allow appropriate preparations to be made in each site.
Further, given the temporal nature of pregnancy, it is
not possible to hold randomisation until all women in
each participating site have been recruited, because
some women would have given birth by the time the last
woman would have been recruited. However, as with
cluster trials in which the participants cannot be blinded
to the intervention, once the sites had been randomised,
it is possible that recruitment of women to the trial was
influenced by the knowledge of whether or not they
would receive the OptiBIRTH intervention at that site.
Hence, the primary analyses for the trial (see below) will
consider data at the level of each site as a whole, rather
than at the level of the women who were approached
and formally recruited.
Within each of the three countries, the maternity units
were matched by their annual number of births and then
by VBAC rate. They were matched in either pairs or
triplets and then randomised 1:1 or 2:1 to intervention
or control, respectively. The randomisation was done
using the random number generator in Microsoft Excel
[RAND], with the first site in each matched pair or trip-
let being assigned a random number between 0 and 1. If
the number was below 0.500, the site was allocated
‘OptiBIRTH intervention’. If it was above 0.500, the site
was allocated ‘control’. If the number had been exactly
0.500 the randomisation would have been done again,
but this did not happen. Where a matched pair had been
formed, the second site was automatically allocated the
opposite of the first site. Where a matched triplet had
been formed, if the first site was allocated to the control
group, the other two sites were automatically allocated
to the intervention group. If the first site was allocated
to the intervention group, the randomisation was re-
peated for the second site, and the third site was auto-
matically allocated to the opposite of the allocation for
the second site.
The randomisations were done in the presence of a
witness who was unaware of which site was associated
with which code within the pairs and triplets until after
the allocations were complete. Although we recognise
that it is not possible to mask the allocation of the sites
from people who are familiar with them, including
pregnant women and practitioners, further informa-
tion on the sites is not included in this published
protocol, to reduce the possibility that this knowledge
might influence the referral of pregnant women to
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the participating sites during the recruitment phase
for the trial or the follow-up period for the primary
outcome analysis (see below).
Eligibility criteria for participants
To be eligible for inclusion, pregnant women at a par-
ticipating site must meet the following criteria:
1. Be ≥18 years of age at the time of booking
2. Have had one previous caesarean section using a
lower segment transverse incision (not a classical/high
vertical incision)
3. Speak and understand a language for at least one of
the trial countries (English, German or Italian)
4. Provide informed consent to participate in the study
If a woman is known to have a multiple pregnancy at
the time of the booking, she is not eligible.
Training and support for trial sites
Staff members at all study sites are proficient in mater-
nity care provision and in caring for women with one
previous caesarean section. They are provided with in-
formation on the trial by members of the research team,
including the national postdoctoral researchers and prin-
cipal investigators.
Interventions
Participating sites were randomised to either interven-
tion or control.
OptiBIRTH intervention
Sites randomised to the intervention group will receive a
complex innovative programme of evidence-based ante-
natal strategies, incentives and activities to increase the
empowerment, engagement and involvement of women
with a history of one previous caesarean section. Full de-
tails of the OptiBIRTH intervention will be published in
a separate paper but, in summary, it seeks to empower
women and to develop a community of practice in the
site, with the intention of increasing the VBAC rate. The
package includes face-to-face educational sessions about
VBAC for clinicians in each site, specially designed ante-
natal classes for the recruited women and an optional
interactive website and applications, which will assist
them in setting personal goals to achieve their optimal
birth outcome. Building a community of practice at the
site, which would be more favourable to VBAC, should
impact all women at the site, not just those who attend
the antenatal classes or access the online resources.
Control
Sites randomised to the control group will receive the
current standard of care in that maternity unit.
Process evaluation
The OptiBIRTH research team has developed a process
evaluation plan to explore and document the implemen-
tation of the OptiBIRTH intervention, and how it was
received by key stakeholders and to identify factors that
could explain variation in outcomes across intervention
sites. This evaluation will include details of the attendance
of clinicians at their face-to-face educational sessions, the
attendance of women at the antenatal classes and their
use of the online resources. It will also include the gather-
ing of information from both clinicians and women on
their experiences with the OptiBIRTH intervention and
the various activities and resources made available to
them. In addition, the sites in which the intervention was
implemented will be described, and findings will be used
to assist in interpretation of the trial results. Such process
evaluations are particularly important in cluster rando-
mised trials, where a ‘standardised’ intervention may, in
fact, be implemented in different ways or be the subject of
different reactions [31]. A resulting ‘lack of effect’ may
thus merely indicate problems with implementation rather
than true ineffectiveness [8].
Outcome measures
Primary
The primary outcome measure will be the VBAC rates
for women with one previous caesarean section for each
site comparing the years before and after the delivery of
the intervention. This is calculated as the number of
women who gave birth by spontaneous vaginal delivery
or with the use of ventouse or forceps after a single pre-
vious caesarean section, divided by the total number of
women who gave birth at the site after a single previous
caesarean section.
Secondary
Secondary maternal outcomes collected at and shortly
after birth are described below:
1. Use of health care and other resources
2. Labour onset (spontaneous, induced, etcetera)
3. Spontaneous rupture of membranes
4. Acceleration of labour (artificial rupture of
membranes, oxytocin use)
5. Analgesia during labour
6. Length of labour
7. Mode of birth
8. Perineal trauma (1st, 2nd, 3rd, 4th degree tear;
episiotomy)
9. Maternal morbidity (for example: post-partum
haemorrhage, uterine rupture, wound breakdown,
admission to intensive care unit, etcetera)
10. Maternal death
11. Length of postnatal hospital stay (days)
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Secondary neonatal outcomes collected during preg-
nancy and at, and shortly after, birth are described below:
1. Fetal demise during pregnancy (miscarriage,
stillbirth, intrauterine death)
2. Gestation at birth
3. Apgar scores at 1 and 5 minutes after birth
4. Umbilical arterial and venous cord pH and base
excess
5. Neonatal resuscitation
6. Admission to neonatal intensive care unit
7. Neonatal mortality
8. Neonatal morbidity (for example: seizures,
hypoxic-ischemic encephalopathy, intracranial
haemorrhage, meconium aspiration syndrome,
renal failure, etcetera)
9. Length of neonatal postnatal stay (days)
Secondary maternal outcomes collected at 3 months
post-partum are described below:
1. Satisfaction (with the intervention, mode of birth
and participation in trial)
2. Breastfeeding (initiation and over the first 3 months
post-partum)
3. Quality of life (measured by SF-36)
4. Use of health care and other resources
Sample size assumptions and estimates
The sample size for this cluster randomised trial was de-
rived by adjusting an estimate for the sample size for an
individually randomised trial to allow for clustering. This
was done by inflating the estimate by the design effect
given by 1 + (ñ-1)ρ, where ñ is the average cluster size
and ρ is the estimated intra-class correlation coefficient
(ICC) for this study. With a background proportion of
successful VBAC of 25 % and an ICC of 0.05, 12 trial
units would be required, each containing 120 participat-
ing women (840 women in the intervention group and
840 women in the control group), to detect a 15 per-
centage point difference in successful VBACs (that is, an
increase from 25 % in the control group to 40 % in the
intervention group), with power of at least 80 % and an
alpha level of 0.05. If the true ICC values are less than
0.05, the power of the study will increase. To allow for a
loss to follow-up of 20 % of women and the possibility
that one site per country will drop out of the trial, 15
trial units (16 maternity sites) were randomised across
three countries.
Recruitment and consent
In order to maintain the integrity of the cluster random-
isation, each woman in each site will be screened for
eligibility for OptiBIRTH, using a pre-designed Trial
Screening and Register Form. Although all those who
are eligible could be considered to have been rando-
mised, it will only be possible to use data for those who
give their consent.
Following screening, women who are judged eligible
for OptiBIRTH will be informed of the study verbally
and will receive a ‘study information pack’, including a
detailed information leaflet and a consent form. This will
be done by the midwives who are providing their ante-
natal care and takes place at the earliest opportunity in
the woman’s interaction with the maternity unit. If a
woman presents too late in her pregnancy to avail her-
self of the antenatal classes or the online resources, she
will not be approached about OptiBIRTH. Women, hav-
ing had time to consider the study information and
agreeing to participate in the trial, will sign and return
the consent form to the local research office. On receipt
of the signed consent form, women will be contacted by
the local postdoctoral researcher (or designated hospital
midwife) and provided with further details on accessing
the trial processes (intervention sites only).
When seeking their consent, women will be offered
the opportunity to participate in the trial at one of two
levels, which relate to both their use of the various
elements in the intervention and the provision of data. If
the OptiBIRTH intervention succeeds in building a com-
munity of practice at the site which is more favourable
to VBAC, this should impact all women at the site, not
just those who choose the ‘full participation’ option and
attend the antenatal classes or access the online
resources.
The two levels of participation are as follows:
1. Full participation: women in the intervention sites
would choose this option if they wanted to be able
to attend the OptiBIRTH antenatal classes and
access the online resources. In both the intervention
and the control sites, women who choose this
option are agreeing to complete the health surveys
and a diary of healthcare expenses and to allow the
OptiBIRTH researcher to access their healthcare
records and those of their babies.
2. Routine data only: women choose this option if they
are willing to give permission for the OptiBIRTH
researcher to access the healthcare records for
themselves and their baby, but do not wish to attend
the antenatal classes or access the online resources
(in the intervention sites) or to complete the health
surveys and diary of healthcare expenses (in both
intervention and control sites).
Data collection
Pre-designed data extraction forms will be used to
collect all study outcome data. These include forms for
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participant self-report of antenatal and postnatal health
and wellbeing and healthcare resource use, as well as ex-
penditure surveys and clinician-report labour and birth
outcome data collection forms. Where relevant, the
forms will be provided to the participants and they will
be asked to complete and return them to their hospital.
Other data (such as routine data on birth events) will be
collected at each participating site by each country’s na-
tional postdoctoral researcher or a designated research
assistant. Each national coordinating team will use spe-
cially created Microsoft Access forms to enter and store
their data before submission of the data in encrypted
form to the OptiBIRTH trial and data management
centre. The relevant data are to be submitted for each
woman at each stage in the OptiBIRTH trial (from
screening through to the data gathered on the postnatal
follow-up forms). Each country’s national coordinating/
postdoctoral researcher will audit approximately 5 % of
the records for each participating site during their visits
to those sites.
Data management and validation
Data will be submitted by encrypted email to OptiBIRTH’s
trial and data management centre (Centre for Public
Health, Queen’s University Belfast) monthly and stored in
the trial database (Microsoft Access 2007). Appropriate
validation rules are in place for each field in the
OptiBIRTH data. Cross-validation routines have been
established, where the content of one field would
determine the validity of data in another field. For ex-
ample, if a woman has a spontaneous vaginal birth,
the fields for capturing data following a caesarean
section should not be completed. The OptiBIRTH
trial database will contain identifiable information
and, as such, conforms to legal requirements as defined in
the UK Data Protection Act 1998. In response to this Act,
Queen’s University Belfast issued a Policy Statement and
developed robust data protection recommendations that
the Centre for Public Health at Queen’s University Belfast
adhere to. Given that the database contains identifiable
data, the potential risk associated with this database re-
lates to a potential breach of participant confidentiality,
whereby a party not involved directly in the study gains
access to identifiable data, and the aforementioned pol-
icies and practices are designed to prevent this.
Data analysis
Statistical analysis plans will be prepared for the analyses
of both the clinical and the cost-effectiveness data, and
made available separately to this protocol. Where pos-
sible, the main analysis will be by ‘intention-to treat’ but
this is not always possible in a cluster randomised trial
where, by the nature of the intervention, the re-
cruiters and the potential participants are aware of
their allocated intervention before they are asked to
provide their consent. Therefore, the principal analysis
to test the effect of the intervention at the site level
will compare differences in the primary outcome,
namely the proportions of VBAC, between the inter-
vention and control sites. The comparison of VBAC
rates in each of the participating sites will compare
the change in the VBAC rates in the intervention
sites versus the change in the control sites between
the calendar year 2012 (that is, before the OptiBIRTH
intervention was available to any hospital) and, if
possible, the 12-month period after the month that
the last OptiBIRTH baby is born in each hospital.
However, for some hospitals, it might be necessary to
use the data for the calendar year (that is, January to
December) that follow the birth of the last Opti-
BIRTH baby in that hospital because of the practical
difficulties of accessing hospital level data for periods
other than calendar years.
In addition to the primary analyses at the level of the
hospital, we will analyse the data for the women who
agree to take part in the trial and their babies, in order
to assess the effects of the intervention on the secondary
outcomes listed above. Where outcomes have been col-
lected as continuous variables (for example, duration of
labour) they will be analysed as continuous data to com-
pare the intervention and control sites. Likewise, dichot-
omous data (for example, breast feeding at 3 months)
will be used to compare the proportions in the interven-
tion and control sites. The analyses will adjust for
whether the woman had had any prior vaginal birth or
prior VBAC, and her BMI and age. We will conduct
subgroup analyses for these adjustment variables and the
three countries. Our hypothesis is that the effects of the
intervention will not be so heterogeneous across these
subgroups to invalidate the calculation of an overall re-
sult for the trial as a whole.
Trial oversight
Trial management group
There will be monthly Skype or teleconferences of the
Trial Management Group, comprising the principal
investigators and postdoctoral researchers from each
country, in addition to the principal investigator and
data manager for the trial, the project coordinator for
the OptiBIRTH project as a whole, and other members
of the OptiBIRTH project as appropriate to the specific
meeting.
Trial steering committee
The Trial Steering Committee (TSC) comprises the
members of the overall Steering Committee for the
OptiBIRTH project as a whole. This group meets quar-
terly, usually by Skype or teleconference but with one
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face-to-face meeting per year. Summary reports for each
site, each country and the trial as a whole will be pre-
pared every 3 months for the OptiBIRTH TSC, showing
the data for each 3-month period and for the full
duration of the trial to date. These reports contain data
relating to the management of the trial to show its pro-
gress without revealing interim results.
Data monitoring committee
To optimise participant safety and the scientific integrity
and credibility of the results of the trial, an international
Data Monitoring Committee (DMC) will conduct an in-
terim analysis of data from approximately 400 to 700
women who have birthed and will provide an interim
report. They will be provided with unblinded data on
the VBAC rate at each site in the year before the
OptiBIRTH trial began, the number of women re-
cruited in each site and the proportion of those who
are known to have birthed who did so by spontan-
eous vaginal delivery or with the use of ventouse or
forceps. This initial assessment of the effects of the
intervention on VBAC and safety will influence the
decision on whether control sites should be offered
the intervention on completion of the trial within the
available funding timeframe. The DMC will assess
participant safety and whether either intervention is
showing a much stronger or weaker effect than ex-
pected. It will make recommendations concerning the
future of the study to the TSC.
Ethical considerations
The ethical issues involved in this study are the key prin-
ciples of ensuring the protection of human rights, the
maintenance of scientific integrity, the minimising of
harm and maximising of benefit and ensuring justice
and equity, autonomy and informed consent, confidenti-
ality, data protection and privacy. Ethical approval was
granted by the Faculty of Health Sciences, Trinity
College Dublin, Ireland and regional Research Ethics
Committees for all participating study sites in each par-
ticipating country. A list of the relevant committees was
provided to the journal as part of the approval process
for this manuscript, but, as noted above, identifying in-
formation for the sites is not included in this published
protocol to reduce the possibility that this knowledge
might influence referral of pregnant women to the par-
ticipating sites during the recruitment or follow-up
phases for the trial.
Ancillary studies
Should the opportunity arise to conduct a SWAT (Study
within a Trial) in OptiBIRTH, this will be discussed with
the TSC and implemented with their approval. The
SWAT programme has been developed by the Northern
Ireland Network for Trials Methodology Research as a
means to encourage the conduct of research within re-
search, to reduce uncertainties about the most appropri-
ate and effective methods to use in randomised trials
and other evaluations of health and social care [34, 35].
Dissemination
The main findings of OptiBIRTH will be published
under an Open Access model and will be presented at
relevant national and international conferences. The
current intention is that the analyses for the participat-
ing women will be published following collection of the
final outcome data for all of those women.
Discussion
Recruitment to the OptiBIRTH trial is expected to close
in all sites in 2015, with all participating women ex-
pected to birth by the end of the year. Recruitment has
been slower than anticipated, in part because birth rates
have fallen at several of the sites. As with cluster rando-
mised trials in general, it has not been possible to recruit
all potentially eligible women at each site. Among the
reasons for this are that some of the women who were
offered participation in the trial did not wish to join and
because of challenges in fully initiating the study in each
site. This may introduce differences between the par-
ticipants in the intervention and control sites, which
reinforces the importance of the primary analyses be-
ing a comparison of the VBAC rates for all women
with one previous caesarean section at each site be-
fore and after the study period using routine data
from each site. If the OptiBIRTH intervention suc-
ceeds in increasing VBAC rates, its application across
Europe might avoid 160,000 unnecessary caesarean
sections every year, which occur at an extra direct an-
nual cost of more than €150 million.
Trial status
This protocol was submitted for publication in May
2015 when recruitment was ongoing. The last women
are expected to join the trial by October 2015.
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